Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AZD6244 (ARRY-142886) is an inhibitor of MEK1/2 and can inhibit cell proliferation or induce apoptosis in a cell-type dependent manner. The precise molecular mechanism of AZD6244-induced apoptosis is not clear. To investigate mechanisms of AZD6244 induced apoptosis in human lung cancer, we determined the molecular changes of two subgroups of human lung cancer cell lines that are either sensitive or resistant to AZD6244 treatment. We found that AZD6244 elicited a large increase of Bim proteins and a smaller increase of PUMA and NOXA proteins, and induced cell death in sensitive lung cancer cell lines, but had no effect on other Bcl-2 related proteins in those cell lines. Knockdown of Bim by siRNA greatly increased the IC(50) and reduced apoptosis for AZD6244 treated cells. We also found that levels of endogenous p-Thr32-FOXO3a and p-Ser253-FOXO3a were lower in AZD6244-sensitive cells than in AZD6244-resistant cells. In the sensitive cells, AZD6244 induced FOXO3a nuclear translocation required for Bim activation. Moreover, the silencing of FOXO3a by siRNA abrogated AZD6244-induced cell apoptosis. In addition, we found that transfection of constitutively active AKT up-regulated p-Thr32-FOXO3a and p-Ser253-FOXO3a expression and inhibited AZD6244-induced Bim expression in sensitive cells. These results show that Bim plays an important role in AZD6244-induced apoptosis in lung cancer cells and that the PI3K/AKT/FOXO3a pathway is involved in Bim regulation and susceptibility of lung cancer cells to AZD6244. These results have implications in the development of strategies to overcome resistance to MEK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the induction of BIM proteins by MEK/ERK inhibition (15, 16) can result in BIM being bound and inhibited by anti-apoptotic BCL-2 and/or BCL-XL, which are frequently overexpressed in solid tumors (17).”
From The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism (2015) · cites this paper as [16]
In the citing paper
“BIM protein levels are negatively regulated by the MAPK pathway through ERK-dependent targeting of BIM to proteasomal degradation (37, 38, 42).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Sunters, A., Fernández de Mattos, S., Stahl, M., Brosens, J. J., Zoumpoulidou, G., Saunders, C. A., Coffer, P. J., Medema, R. H., Coombes, R. C., & Lam, E. W.-F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309523200 · Cited by 505
Research works printed but not linked: 35
- [1]Yeh TC Marsh V Bernat BA Ballard J Colwell H 2007 Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13 1576 83 17332304
- [2]Haass NK Sproesser K Nguyen TK Contractor R Medina CA 2008 The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14 230 9 18172275
- [3]Davies BR Logie A McKay JS Martin P Steele S 2007 AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 8 2209 19 17699718
- [4]Huynh H Chow PK Soo KC 2007 AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 6 2468 76 17876044
- [5]Meng J Peng H Dai B Guo W Wang L 2009 High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 8 2073 80 19783898 PMC2835993
- [6]Nordigården A Kraft M Eliasson P Labi V Lam EW 2009 BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood 113 2302 11 19064725 PMC3272395
- [7]Yang JY Chang CJ Xia W Wang Y Wong KK 2010 Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer. Cancer Res 70 4709 18 20484037 PMC2895805
- [9]Cragg MS Kuroda J Puthalakath H Huang DC Strasser A 2007 Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4 1681 89 17973573 PMC2043013
- [10]Pei XY Dai Y Tenorio S Lu J Harada H 2007 MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 110 2092 101 17540843 PMC1976370
- [11]Finnberg N El-Deiry WS 2004 Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther 3 614 6 15254408
- [12]Yang JY Xia W Hu MC 2006 Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29 643 48 16865280 PMC2632978
- [13]Schmidt M Fernandez de Mattos S van der Horst A Klompmaker R Kops GJ 2002 Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22 7842 52 12391153 PMC134724
- [14]Medema RH Kops GJ Bos JL Burgering BM 2000 AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404 782 7 10783894
- [15]Tran H Brunet A Grenier JM Datta SR Fornace AJ Jr 2002 DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296 530 4 11964479
- [16]Brunet A Bonni A Zigmond MJ Lin MZ Juo P 1999 AKT promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857 68 10102273
- [17]Kops GJ de Runiter ND de Vires-Smits AM Powell DR Bos JL 1999 Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398 630 4 10217147
- [18]Yang JY Zong CS Xia W Yamaguchi H Ding Q 2008 ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10 138 48 18204439 PMC2376808
- [19]Ley R Balmanno K Hadfield K Weston C Cook SJ 2003 Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278 18811 6 12646560
- [20]Dijkers PF Medema RH Lammers JW Koenderman L Coffer PJ 2000 Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10 1201 4 11050388
- [21]Gilley J Coffer PJ Ham J 2003 FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162 613 22 12913110 PMC2173804
- [23]Datta SR Dudek H Tao X Masters S Fu H 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 231 41 9346240
- [24]Cardone MH Roy N Stennicke HR Salvesen GS Franke TF 1998 Regulation of cell death protease caspase-9 by phosphorylation. Science 282 1318 21 9812896
- [25]Fernández de Mattos S Villalonga P Clardy J Lam EW 2008 FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cell. Mol Cancer Ther 7 3237 46 18852127 PMC2748241
- [26]Leung KT Li KK Sun SS Chan PK Ooi VE 2008 Activation of the JNK pathway promotes phosphorylation and degradation of BimEL—a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 29 544 51 18174237
- [27]Kelekar A Thompson CB 1998 Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 8 324 30 9704409
- [28]Puthalakath H Strasser A 2002 Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9 505 12 11973609
- [29]Chen X Thakkar H Tyan F Gim S Robinson H 2001 Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20 6073 83 11593415
- [30]Yuan ZQ Feldman RI Sussman GE Coppola D Nicosia SV 2003 AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278 23432 40 12697749
- [31]Clark AS West K Streicher S Dennis PA 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 707 17 12479367
- [32]Hengartner MO 2000 The biochemistry of apoptosis. Nature 407 770 6 11048727
- [33]Janicke RU Sprengart ML Wati MR Porter AG 1998 Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273 9357 60 9545256
- [34]Boulares AH Yakovlev AG Ivanova V Stoica BA Wang G 1999 Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274 22932 40 10438458
- [35]Bursch W 2001 The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 8 569 81 11536007
- [36]Gozuacik D Kimchi A 2004 Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23 2891 906 15077152
- [37]Zong WX Thompson CB 2006 Necrotic death as a cell fate. Genes Dev 20 1 15 16391229
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95
“There were also increases in BIM mRNA levels in these cells, consistent with a contribution of BIM mRNA regulation by the MEK/ERK pathway [41] (Sup.”
BackgroundNangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94
Zaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S., & Sinicrope, F. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657833 · Cited by 59
“However, the induction of BIM proteins by MEK/ERK inhibition (15, 16) can result in BIM being bound and inhibited by anti-apoptotic BCL-2 and/or BCL-XL, which are frequently overexpressed in solid tumors (17).”
BackgroundLeto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
Metadata
- Authors
- Meng, J., Fang, B., Liao, Y., Chresta, C. M., Smith, P. D., & Roth, J. A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-09-27
- Volume
- 5
- Issue
- 9
- Pages
- e13026
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2946397
- OpenAlex
- W2007847006
- Cited by
- 78
- References
- 2
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.